Is There a Chance to Treat Modified Gartland Type IIB Pediatric Supracondylar Humerus Fractures With Closed Reduction and Casting?

Abstract

Wilkins modification of the Gartland classification (WMGC) type IIB supracondylar humeral fractures (SCHFs) are unstable, and their primary treatment is surgery. This study sought to evaluate the chance of closed reduction and long arm cast (CR&LAC) treatment of type IIB fractures. In this retrospective case-control study, pediatric patients with WMGC type II fractures whose initial treatment was CR&LAC were examined. Cases were subdivided according to WMGC. Type IIA and IIB cases were compared in terms of the reduction loss rate and clinical and radiologic results. Then, patients with type IIB fractures who were treated conservatively or surgically were compared in terms of clinical and radiologic results. A total of 817 pediatric SCHFs were examined, of which 233 had type II fractures. This study finally enrolled 87 cases who met the inclusion criteria, including 52 with type IIA fractures and 35 with type IIB fractures. Among those with type IIB fractures, the first-time reduction success rate was 44.3%. Although the probability of a loss of reduction among type IIB fractures in conservative follow-up was ~5 times higher than that among type IIA fractures, all the cases with reduction loss were detected among the first-week controls, and 9 of them were type IIB and 3 were type IIA ( P =0.011). The treatment of 26 (32.9%) cases with type IIB fractures was completed conservatively. There was no difference in the clinical or radiologic comparison results of type IIA and type IIB fractures whose treatment was completed conservatively. There was no clinical or radiologic difference in the comparison of type IIB fractures whose treatment began with CR&LAC but was completed conservatively or surgically. Although the initial reduction success is not high among WMGC type IIB fractures, the results are like those of conservatively managed type IIA fractures if successful reduction is achieved. This study showed that the treatment results of all type II SCHFs with no loss of reduction in the first week after CR&LAC are satisfactory. No reduction loss was observed in any of the cases after the first week. Level III, case-control study.